Global Leading Market Research Publisher QYResearch announces the release of its latest report ”Neurodegenerative Disease IVD – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Neurodegenerative Disease IVD market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Neurodegenerative Disease IVD was estimated to be worth US$ 484 million in 2025 and is projected to reach US$ 704 million, growing at a CAGR of 5.6% from 2026 to 2032.
Neurodegenerative disease IVD (In Vitro Diagnostics) refers to an in vitro detection method and technology system that detects specific biomarker detection in biological samples (such as cerebrospinal fluid, blood, urine, etc.) and combines high-sensitivity detection technology to achieve early diagnosis, disease monitoring and prognosis evaluation of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD). Its core goal is to solve the problems of insufficient sensitivity, strong invasiveness or high cost of traditional diagnostic methods (such as clinical evaluation and imaging examinations), and promote early intervention and precision medicine for these devastating conditions.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6089665/neurodegenerative-disease-ivd
Market Dynamics: The Convergence of Aging Demographics and Diagnostic Innovation
The Neurodegenerative Disease IVD market is propelled by an irreversible demographic tide: global population aging. According to United Nations population projections, the number of individuals aged 65 and above will reach 1.6 billion by 2050, representing a fundamental expansion of the at-risk population for Alzheimer’s and Parkinson’s diseases. This epidemiological shift is amplified by the recent regulatory approval of disease-modifying therapies (DMTs) for Alzheimer’s disease. The FDA’s full approval of Leqembi (lecanemab) in 2025 and the approval of Kisunla (donanemab) established a critical precedent: early diagnosis via validated biomarker detection is now a prerequisite for treatment initiation. This clinical workflow integration creates a structural demand driver for Neurodegenerative Disease IVD that extends beyond traditional diagnostic utility into therapeutic enablement .
The broader neurological biomarkers ecosystem—encompassing Alzheimer’s, Parkinson’s, multiple sclerosis, and related conditions—was valued at approximately $9.6 billion in 2025 and is anticipated to reach $17.85 billion by 2032, growing at a 9.4% CAGR . Within this landscape, Neurodegenerative Disease IVD represents a specialized, high-value segment characterized by rigorous analytical validation requirements and complex regulatory pathways.
Technological Evolution: From CSF to Blood-Based Biomarker Detection
A transformative shift is underway in Neurodegenerative Disease IVD methodology. Historically, cerebrospinal fluid (CSF) analysis—requiring invasive lumbar puncture—has served as the gold standard for AD biomarker assessment, with Fujirebio pioneering CSF assays over 25 years ago. These assays measure four core proteins: Aβ1-42, Aβ1-40, Total Tau, and phospho-Tau, with the Aβ1-42/Aβ1-40 ratio demonstrating diagnostic utility years before symptomatic onset. According to industry analysis, CSF-based testing currently represents approximately 59% of the Alzheimer’s diagnostic market segment, with clinical laboratories progressively transitioning these biomarkers from research tools to routine automated testing platforms .
However, the Neurodegenerative Disease IVD landscape is being reshaped by the emergence of high-sensitivity blood-based biomarker assays. Recent technological breakthroughs in single-molecule array (Simoa) technology, immunoprecipitation-mass spectrometry (IP-MS), and automated immunoassay platforms have enabled reliable quantification of p-Tau217, p-Tau181, GFAP, and NfL from peripheral blood samples. This blood-based biomarker innovation addresses the primary limitation of CSF testing—invasiveness—and dramatically expands the addressable screening population. The clinical community now anticipates that blood-based testing will democratize access to Alzheimer’s diagnostics, enabling primary care deployment and population-level risk stratification previously constrained to specialized neurology centers.
Competitive Landscape and Strategic Positioning
The Neurodegenerative Disease IVD market is segmented as below, reflecting a concentrated ecosystem of established diagnostics leaders and specialized innovators:
ADx Neurosciences, Analytik Jena, Beckman Coulter, Creative Biolabs, Fujirebio, Genemedi, Medix Biochemica, Revvity, Roche Diagnostics.
Roche Diagnostics maintains a commanding position in the Neurodegenerative Disease IVD space through its Elecsys immunoassay platform, which offers fully automated CSF biomarker panels with CE marking and FDA clearance. Fujirebio, as the pioneer in AD CSF testing, continues to hold significant market share, particularly in Europe and Asia-Pacific, with its Lumipulse G system providing quantitative Aβ and Tau measurements. Revvity (formerly PerkinElmer) has strategically positioned itself in the emerging blood-based biomarker segment through its EUROIMMUN p-Tau181 assay portfolio and research-use-only multiplex panels .
Segmentation Analysis: Type and Application
Segment by Type
- Protein Biomarker Detection: The dominant segment, encompassing Aβ peptides, Tau isoforms (total and phosphorylated), neurofilament light chain (NfL), and GFAP. This category benefits from established clinical validation and automated platform integration.
- Nucleic Acid Biomarker Detection: Emerging segment focusing on genetic risk variants (APOE ε4), microRNA signatures, and epigenetic markers. This category currently occupies a niche position but holds promise for polygenic risk scoring applications.
- Others: Including metabolic biomarkers and emerging multi-analyte profiling approaches.
Segment by Application
- Alzheimer’s Disease: The largest application segment, driven by DMT approval tailwinds and expanding screening guidelines. Recent National Institute on Aging and Alzheimer’s Association (NIA-AA) revised diagnostic criteria now incorporate blood-based biomarker results into clinical decision frameworks.
- Parkinson’s Disease: Representing the second-largest segment, with α-synuclein seed amplification assays (SAA) demonstrating 88-95% diagnostic sensitivity in recent validation studies.
- Huntington’s Disease: Genetic testing for CAG repeat expansion remains the gold standard; Neurodegenerative Disease IVD applications focus on disease progression monitoring via NfL quantification.
- Amyotrophic Lateral Sclerosis (ALS): Emerging applications in differential diagnosis and therapeutic response monitoring.
- Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) : Niche applications addressing differential diagnosis challenges within the atypical parkinsonism spectrum.
- Others: Including frontotemporal dementia, Lewy body dementia, and vascular cognitive impairment.
Regulatory and Reimbursement Dynamics
The Neurodegenerative Disease IVD market is navigating an evolving regulatory landscape. In the United States, the FDA’s proposed rule on Laboratory Developed Tests (LDTs), published in October 2023 and finalized with phased implementation through 2028, will progressively subject high-complexity Neurological biomarkers assays to premarket review requirements. This regulatory shift favors established IVD manufacturers with quality system infrastructure and clinical trial capabilities while potentially constraining laboratory-developed test offerings from academic medical centers.
Concurrently, reimbursement policy is adapting to accommodate blood-based biomarker testing. The Centers for Medicare & Medicaid Services (CMS) finalized a national coverage determination in 2025 for beta-amyloid PET imaging, establishing precedent for biomarker-directed coverage. Industry stakeholders anticipate parallel coverage expansion for blood-based Alzheimer’s diagnostics meeting analytical validity thresholds defined by the Global CEO Initiative on Alzheimer’s Disease performance standards.
Exclusive Insight: Comparative Analytical Performance and Clinical Validation Hurdles
A critical differentiator in the Neurodegenerative Disease IVD market is analytical performance—specifically, concordance with amyloid PET or CSF reference standards. Independent comparative studies indicate that plasma p-Tau217 assays achieve area under the curve (AUC) values of 0.92-0.96 for detecting amyloid pathology, approaching CSF performance metrics. However, significant inter-platform variability persists: assays from different manufacturers demonstrate up to 30% discordance in binary classification of amyloid status when applied to identical patient cohorts. This analytical heterogeneity represents a barrier to clinical standardization and underscores the competitive advantage accruing to manufacturers investing in rigorous multi-site validation studies.
Furthermore, a nuanced divergence exists between discrete and process-oriented diagnostic workflows in Neurodegenerative Disease IVD adoption. Academic medical centers and specialized memory clinics—analogous to discrete manufacturing with variable case-mix—prioritize assay accuracy and novel biomarker breadth. In contrast, high-volume reference laboratories and primary care networks—resembling process manufacturing with standardized throughput—emphasize automation compatibility, turnaround time, and cost-per-test economics. Vendors successfully navigating both segments require modular platform architectures accommodating divergent operational priorities.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
